The past few years have shown an ongoing interest in lipoprotein (a)(Lp (a)), a lipid
molecule that has been proven to have atherogenic, thrombogenic, and inflammatory …

Introduction There is abundant evidence that elevated lipoprotein (a)[LP (a)] associates with
cardiovascular risk. Most lipid modifying therapies don't reduce Lp (a), but new technologies …

Lipoprotein (a)(Lp (a)) is a complex circulating lipoprotein, and increasing evidence has
demonstrated its role as a risk factor for atherosclerotic cardiovascular disease (ASCVD) …

Latest developments in the treatment of lipoprotein (a) : Current Opinion in Lipidology Latest
developments in the treatment of lipoprotein (a) : Current Opinion in Lipidology Log in or …

Background: Lipoprotein (a)[Lp (a)] is a molecule that induces inflammation of the blood
vessels, atherogenesis, valvular calcification, and thrombosis. Methods: We review the …

Abstract Lipoprotein (a), or Lp (a), is structurally like low‐density lipoprotein (LDL) but differs
in that it contains glycoprotein apolipoprotein (a)[apo (a)]. Due to its prothrombotic and …

Objective To review evidence of existing and new pharmacological therapies for lowering
lipoprotein (a)(Lp [a]) concentrations and their impact on clinically relevant outcomes …

Lp (a) remains the last major lipoprotein disorder without any specific therapy. With the
strong and accumulating data on its role as a causal risk factor for CVD, a rationale exists to …

Elevated plasma level of LDL-cholesterol (LDL-C) is a modifiable major risk factor for
atherosclerotic cardiovascular disease. Several LDL-C-lowering agents successfully reduce …

Atherosclerosis is a chronic process characterized by inflammation and the progressive
accumulation of inflammatory cells and lipids in the blood vessel wall, resulting in narrowing …